个人简介

Dr Webster completed a Bachelor of Medical Science (Hons I) at Charles Sturt University in 2000. She then joined the Department of Translational Oncology at Westmead Millennium Institute (The University of Sydney) where she worked as a research assistant, completed her PhD studies and gained invaluable post-doctoral experience. Dr Webster's PhD studies focused on identifying better markers of aggressiveness in early stage breast cancer using standard histopathological and contemporary molecular biology methods. During her PhD and post-doctoral studies she also spent a considerable amount of time working at the National Institutes of Health, Washington DC. Dr Webster maintains a particular research interest in breast cancer histopathology and molecular pathogenesis. In February 2008 she joined the academic team in the School of Biomedical Sciences at Charles Sturt University.

研究领域

histology, molecular biology and bioinformatics

Dr Webster is an enthusiastic researcher with significant experience in histology, molecular biology and bioinformatics. To date, Dr Webster's research projects have focussed on translational oncology and she remains committed to addressing research questions that have a direct impact on the care of patients diagnosed with breast cancer. Current Research Projects: Analysis of cancer screening patterns among migrants living in regional and rural New South Wales. Tracing the origin of variable malignant potential in breast cancer. Enhancing access, equity and student learning through the use of virtual microscopy in histology and histopathology. Prognostic value of oestrogen receptor alpha, oestrogen receptor beta and progesterone receptor expression in adult-type granulosa cell tumours of the ovary. Detection of lymphatic invasion in breast core biopsies using D2-40 immunohistochemistry.

近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Hutton SM, Webster LR, Nielsen S, Leung Y, Stewart CJR (2012). Prognostic value of oestrogen receptor alpha, oestrogen receptor beta and progesterone receptor expression in adult-type granulosa cell tumours of the ovary. Pathology, 44(7):611-616. Balleine RL *, Webster LR*, Davis S, Salisbury EL, Palazzo JP, Schwartz GF, Cornfield DB, Walker RL, Byth K, Clarke CL, Meltzer PS (2008) (* these authors contributed equally to this study). Molecular grading of ductal carcinoma in situ of the breast. Clinical Cancer Research, 14(24):8244-52. Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ (2008). Poor prognosis ER-positive breast cancer identified by histopathologic sub-classification. Clinical Cancer Research, 14(20):6625-33. Guminski AD, Balleine RL, Chiew YE, Webster LR, Tapner M, Farrell GC, Harnett PR, de Fazio A (2006) MPR2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian cancer. Gynecologic Oncology, 100:239-46. Webster LR, Bilous AM, Willis L, Burgemeister FC, Salisbury ELC, Clarke CL, Balleine RL (2005) Histopathologic indicators of breast cancer biology: insights from population mammographic screening. British Journal of Cancer, 92:1366-1371. Balleine RL, Earls PJ, Webster LR, Mote PA, de Fazio A, Harnett PR, Clarke CL (2004) Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma. The International Journal of Gynecological Pathology, 23:138-44. Moriarty HT & Webster LR (2003) Fragile sites and bladder cancer. Cancer, Genetics and Cytogenetics, 140:89-98 (review). Webster LR, McKenzie GH, Moriarty HT (2002) Organophosphate-based pesticides and genetic damage implicated with bladder cancer. Cancer, Genetics and Cytogenetics, 133:112-117. Webster LR, Moriarty HT (2001) Optimisation of aphidicolin concentration for fragile site expression. The Journal of the Association of Genetic Technologists, 27:41-43.